Celgene Corporation (CELG): Today's Featured Drugs Laggard
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 2.8%. By the end of trading, Celgene Corporation fell $4.20 (-3.0%) to $136.96 on average volume. Throughout the day, 2,629,291 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,690,400 shares. The stock ranged in price between $136.60-$139.93 after having opened the day at $139.36 as compared to the previous trading day's close of $141.16. Other companies within the Drugs industry that declined today were:
(
), down 40.8%,
(
), down 19.8%,
(
TheStreet Recommends
), down 11.5% and
(
), down 9.4%.
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $56.9 billion and is part of the health care sector. Shares are up 76.2% year to date as of the close of trading on Monday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.
TheStreet Ratings rates
Celgene Corporation
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
- You can view the full Celgene Corporation Ratings Report.
On the positive front,
Catalyst Pharmaceutical Partners
(
), up 41.5%,
(
), up 22.1%,
(
), up 17.5% and
(
), up 9.6%.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
